Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07116499 · ClinicalTrials.gov registry record · Phase 2
A Study of K-645 in the Treatment of Multiple Migraine Attacks
A Phase 2 study, sponsored by Kallyope.
- Terminated
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
NCT07116499: Clinical Trial Phase 2 study, sponsored by Kallyope.
NCT07116499 is a Phase 2 study that was terminated before completion, run by Kallyope. The registered enrollment target is 134 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07116499, a Phase 2 study, was terminated before completion, sponsored by Kallyope.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine.
Interventions
- DRUG Placebo
- DRUG K-645 dose level 1
- DRUG K-645 dose level 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2025-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07116499
The ClinicalTrials.gov registry entry for NCT07116499 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kallyope, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07116499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07116499 about?
NCT07116499 is a clinical study titled "A Study of K-645 in the Treatment of Multiple Migraine Attacks". This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine.
What is the current status of trial NCT07116499?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2025-08-12. Estimated completion is 2025-11-07.
What interventions are being tested in trial NCT07116499?
The interventions under investigation include: Placebo (DRUG), K-645 dose level 1 (DRUG), K-645 dose level 2 (DRUG).
Who is sponsoring clinical trial NCT07116499?
This trial is sponsored by Kallyope, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.